E. Ohman J or Asset Management AB Cuts Stock Holdings in Gilead Sciences, Inc. $GILD

E. Ohman J or Asset Management AB trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.6% during the 1st quarter, Holdings Channel reports. The firm owned 382,002 shares of the biopharmaceutical company’s stock after selling 14,123 shares during the quarter. Gilead Sciences comprises approximately 1.4% of E. Ohman J or Asset Management AB’s portfolio, making the stock its 11th biggest holding. E. Ohman J or Asset Management AB’s holdings in Gilead Sciences were worth $53,240,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of GILD. Paulson Wealth Management Inc. grew its stake in Gilead Sciences by 1.8% in the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after buying an additional 67 shares in the last quarter. Essex Financial Services Inc. raised its position in shares of Gilead Sciences by 0.9% during the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after buying an additional 71 shares in the last quarter. Alpha Cubed Investments LLC raised its position in shares of Gilead Sciences by 1.1% during the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after buying an additional 75 shares in the last quarter. Personal CFO Solutions LLC lifted its holdings in shares of Gilead Sciences by 1.7% during the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after acquiring an additional 76 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 1.7% during the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock worth $546,000 after acquiring an additional 76 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

GILD opened at $123.76 on Friday. Gilead Sciences, Inc. has a 12 month low of $104.46 and a 12 month high of $157.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The business’s 50-day moving average price is $131.66 and its 200-day moving average price is $134.21. The company has a market cap of $153.66 billion, a P/E ratio of 16.86 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same period in the prior year, the business posted $1.81 EPS. Gilead Sciences’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post -0.8 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio is 44.69%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Needham & Company LLC reissued a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a research note on Monday, February 23rd. Wall Street Zen cut Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Leerink Partners decreased their price objective on Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Citigroup boosted their target price on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 target price on shares of Gilead Sciences in a research note on Tuesday, June 16th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $158.41.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction on Monday, June 1st. The shares were sold at an average price of $131.46, for a total value of $1,971,900.00. Following the transaction, the chief executive officer directly owned 617,567 shares of the company’s stock, valued at $81,185,357.82. The trade was a 2.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the transaction, the insider owned 125,779 shares in the company, valued at $16,513,524.91. The trade was a 18.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 68,000 shares of company stock worth $8,930,150. Insiders own 0.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.